Global Cancer Tubulin Inhibitors Market Data Survey Report 2013-2025

Table of Contents

1 Global Market Overview

• 1.1 Scope of Statistics
  • 1.1.1 Scope of Products
  • 1.1.2 Scope of Manufacturers
  • 1.1.3 Scope of Application
  • 1.1.4 Scope of Type
  • 1.1.5 Scope of Regions/Countries
• 1.2 Global Market Size

2 Regional Market

• 2.1 Regional Production
• 2.2 Regional Demand
• 2.3 Regional Trade

3 Key Manufacturers

• 3.1 Abraxis Biosciences
  • 3.1.1 Company Information
  • 3.1.2 Product & Services
  • 3.1.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.1.4 Recent Development
• 3.2 Agensys
  • 3.2.1 Company Information
  • 3.2.2 Product & Services
  • 3.2.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.2.4 Recent Development
• 3.3 Amgen
  • 3.3.1 Company Information
  • 3.3.2 Product & Services
  • 3.3.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.3.4 Recent Development
• 3.4 Celgene
  • 3.4.1 Company Information
  • 3.4.2 Product & Services
  • 3.4.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.4.4 Recent Development
• 3.5 Eagle Pharmaceuticals
  • 3.5.1 Company Information
  • 3.5.2 Product & Services
  • 3.5.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.5.4 Recent Development
• 3.6 Endocyte
  • 3.6.1 Company Information
  • 3.6.2 Product & Services
  • 3.6.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.6.4 Recent Development
• 3.7 Genentech
  • 3.7.1 Company Information
  • 3.7.2 Product & Services
  • 3.7.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.7.4 Recent Development
• 3.8 Immunogen
  • 3.8.1 Company Information
  • 3.8.2 Product & Services
  • 3.8.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.8.4 Recent Development
• 3.9 Modra Pharmaceuticals
  • 3.9.1 Company Information
  • 3.9.2 Product & Services
  • 3.9.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.9.4 Recent Development
• 3.10 Pierre Fabre
  • 3.10.1 Company Information
  • 3.10.2 Product & Services
  • 3.10.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.10.4 Recent Development
• 3.11 Roche
  • 3.11.1 Company Information
  • 3.11.2 Product & Services
  • 3.11.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.11.4 Recent Development
• 3.12 Sanofi-Aventis
  • 3.12.1 Company Information
  • 3.12.2 Product & Services
  • 3.12.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
  • 3.12.4 Recent Development
• 3.13 Seattle Genetics
  • 3.13.1 Company Information
  • 3.13.2 Product & Services
  • 3.13.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
• 3.14 Tocris Bioscience
  • 3.14.1 Company Information
  • 3.14.2 Product & Services
  • 3.14.3 Business Data (Capacity, Sales Revenue, Volume, Price, Cost and Margin)

4 Major Application

• 4.1 Non Small Cell Lung Cancer
  • 4.1.1 Overview
  • 4.1.2 Non Small Cell Lung Cancer Market Size and Forecast
• 4.2 Prostate Cancer
  • 4.2.1 Overview
  • 4.2.2 Prostate Cancer Market Size and Forecast
• 4.3 Breast Cancer
  • 4.3.1 Overview
  • 4.3.2 Breast Cancer Market Size and Forecast
• 4.4 Colorectal Cancer
  • 4.4.1 Overview
  • 4.4.2 Colorectal Cancer Market Size and Forecast
• 4.5 Ovarian Cancer
  • 4.5.1 Overview
  • 4.5.2 Ovarian Cancer Market Size and Forecast

5 Market by Type

5.By Docetaxel

• 5.1 Docetaxel
  • 5.1.1 Overview
  • 5.1.2 Docetaxel Market Size and Forecast
• 5.2 Trastuzumab Emtansine
  • 5.2.1 Overview
  • 5.2.2 Trastuzumab Emtansine Market Size and Forecast
• 5.3 Abraxane
  • 5.3.1 Overview
  • 5.3.2 Abraxane Market Size and Forecast
• 5.4 Brentuximab Vedotin
  • 5.4.1 Overview
  • 5.4.2 Brentuximab Vedotin Market Size and Forecast
• 5.5 Cabazitaxel
  • 5.5.1 Overview
  • 5.5.2 Cabazitaxel Market Size and Forecast

6 Price Overview

• 6.1 Price by Manufacturers
• 6.2 Price by Application
• 6.3 Price by Type

7 Conclusion